Skip to content
DataLookout
Menu

FIL_MOZARTNCT06492837

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Trial sites reduced: 24 → 20 locations
    v6
  2. Minor Site details revised at 4 of 24 sitesv5
  3. Minor Site details revised at 13 of 24 sitesv4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 20 to 24
    • Start date changed from estimate of Sep 15, 2024 to Oct 23, 2024
    v3
  5. Minor Study title shortened, about 2 wordsv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Complete Response Rate (CRR)
Timeframe: 36 months

Secondary (10)

Overall Response Rate (ORR), Partial Response (PR) Rate at the end of induction treatment (EOI)
Overall Response Rate (ORR), Partial Response (PR) Rate at the end of maintenance (EOT, end of treatment)
Progression Free Survival (PFS)
Overall Survival (OS)
Duration of Response (DOR)
Show 5 moreShow less
Duration of Complete Response (DOCR)
Time-to-next-treatment (TTNT)
Event free survival (EFS)
Frequency and severity of Adverse Events (AEs) and Serious AEs (SAEs)
Frequency and severity of cytokine release syndrome (CRS) and Neurological Adverse Events (NAE)

Arms and interventions

Mosunetuzumab in combination with ZanubrutinibExperimental

Pre-phase: Zanubrutinib 320 mg daily by mouth (D-15 to D-1) Induction phase cycle 1 (Q21 days): * Zanubrutinib 320 mg daily by mouth (D1-21) * Mosunetuzumab 5 mg, SC (D1) * Mosunetuzumab 45 mg, SC (D8) * Mosunetuzumab 45 mg, SC (D15) Induction phase cycles 2-12 (Q28 days): * Zanubrutinib 320 mg daily by mouth (D1-28) * Mosunetuzumab 45 mg, SC (D1) Maintenance phase cycles 13-24 (Q28 days): Zanubrutinib 320 mg daily by mouth (D1-28) Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events.

Drugs: Mosunetuzumab in combination with Zanubrutinib

Sites

20 sites in 2 countries

Italy 16, Australia 4